Califano, R., Passaro, A., Tan, J., Blasco, A., Li, J., Baldotto, C. S. D. R., Campelo, R. G., Sharma, R., Reckamp, K. L., Mashru, S. H., Takahashi, T., Chu, P., Kumar, S., Luo, X., Zhang, J., Curtin, J. C., Cortot, A. B. (2025). Amivantamab plus chemotherapy vs chemotherapy in
            <i>EGFR</i>
            -mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.8639